The city of Houston, Texas, currently has 161 active clinical trials seeking participants for Breast Cancer research studies.
Trial of PreoperAtive Radiation (TOPAz): a Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy with Immediate Autologous Breast Reconstruction with Integrated Nanomechanical Biomarker Evaluation
NCT05774678
Recruiting
To compare the outcomes of and responses to 2 different radiation therapy schedules (the standard radiation amount and number of doses versus less radiation and fewer doses) that are being given before having breast cancer surgery (cancer removal and reconstruction).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
NCT06318897
Recruiting
To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Register for Updates
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
NCT04038619
Recruiting
This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effectively reduce the incidence of immune checkpoint inhibitor-induced diarrhea/colitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Colitis, Diarrhea, Malignant Genitourinary System Neoplasm, Melanoma, Lung Cancer, Ovarian Cancer, Uterine Cancer, Breast Cancer, Cervical Cancer
Register for Updates
Comprehensive Outcomes for After Cancer Health
NCT05349227
Recruiting
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to participate in a randomized wait-list control study. Those in the intervention group will receive 6 months of digital coaching up front followed by 6 months of ongoing monitoring via patient reported and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas +1 locations
Conditions: Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Survivorship, Endometrial Cancer, Head and Neck Cancers, Prostate Cancers, Geriatric Oncology, Metastatic Breast Cancer, Metastatic Cancer
Register for Updates
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
NCT04503265
Recruiting
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
Register for Updates
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
NCT03941756
Recruiting
This pilot trial studies whether a procedure called lymphovenous bypass would prevent lymphedema (arm swelling) in patients with inflammatory breast cancer or non-inflammatory breast cancer that has spread to nearby tissues or lymph nodes or melanoma. The lymphovenous bypass procedure creates a path for lymphatic fluid to flow away from the arms. It is usually done after a diagnosis of lymphedema. In this study, giving lymphovenous bypass before underarm lymph node surgery may help prevent lymph... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Anatomic Stage III Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Melanoma
Register for Updates
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT06103864
Recruiting
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Research Site, Houston, Texas +2 locations
Conditions: Breast Cancer
Register for Updates
Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer
NCT05042687
Recruiting
To evaluate the diagnostic performance of Tc99m sestamibi (MBI) compared to breast MRI in women who are at high risk for developing breast cancer. To assess the relationship of tumor size, histologic subtype and location of lesion and how it affects lesion conspicuity and sensitivity in MBI detected cancers.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371
Recruiting
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: * Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab * Learn more about the side effects of BT5528 * Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Register for Updates
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
NCT06085833
Recruiting
This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the gold standard of histopathological assessment. The study involves patients with suspicious breast lesions who will undergo a breast biopsy procedure indicated by standard of care. The nanomechanical phenotype will be measured on the freshly obtained breast biopsies or tissue from breast surgeries.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT05919108
Recruiting
This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving neratinib in addition to normal therapy may work better in treating cancer than the endocrine therapy patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
Register for Updates
ATEMPT 2.0: Adjuvant T-DM1 Vs TH
NCT04893109
Recruiting
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer, HER2-positive Breast Cancer
Register for Updates